Core Insights - Firefly Neuroscience has launched its new 'CLEAR' Platform, which enhances EEG data quality and processing speed, utilizing NVIDIA's L40S GPU technology [1][3] - The CLEAR Platform significantly improves the reliability of EEG recordings by reducing noise and artifacts, enabling better detection of neural biomarkers for neurological and psychiatric conditions [2][4] - The platform achieves a 60-80% improvement in processing times, leveraging advanced signal processing and machine learning techniques [3][4] Company Overview - Firefly Neuroscience is focused on developing AI-driven solutions to improve brain health outcomes for patients with neurological and mental disorders [5][6] - The company has built a comprehensive database of brain wave tests over the past 15 years, securing patent protection and achieving FDA clearance for its Brain Network Analytics (BNA™) technology [5][6] - BNA™ technology aims to enhance diagnostic and treatment monitoring methods for various conditions, including depression, dementia, and ADHD [5][6]

Core Insights - Firefly Neuroscience has launched its new 'CLEAR' Platform, which enhances EEG data quality and processing speed, utilizing NVIDIA's L40S GPU technology [1][3] - The CLEAR Platform significantly improves the reliability of EEG recordings, enabling better detection of neural biomarkers for neurological and psychiatric conditions [2][4] - The company aims to leverage the CLEAR Platform as a key component of its growth strategy, focusing on transforming neuroscience and clinical development through AI and EEG technology [4][5] Company Overview - Firefly Neuroscience, Inc. is an AI company dedicated to improving brain health outcomes for patients with neurological and mental disorders [5] - The company has developed the FDA-510(k) cleared Brain Network Analytics (BNA™) technology, which enhances diagnostic and treatment monitoring for various conditions [5][6] - Firefly has built a comprehensive database of over 17,000 standardized EEGs, which supports its innovative solutions in clinical settings [6]

Core Points - Firefly Neuroscience, Inc. will be added to the Russell Microcap Index effective June 30, 2025, marking a significant milestone for the company since its Nasdaq listing less than a year ago [2][4] - The Russell indexes are utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3] - The CEO of Firefly highlighted the company's achievements in 2025, including the discovery of a cognitive brain age biomarker, acceptance into the NVIDIA Connect program, and expansion through the acquisition of Evoke Neuroscience [4] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its FDA-cleared Brain Network Analytics (BNA™) technology [5] - The BNA™ technology is designed to enhance diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD [5] - Firefly has developed its BNA™ using AI and machine learning on a proprietary database of over 17,000 patients, providing clinicians with insights into brain function to improve diagnosis and treatment [6]

Core Insights - Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., marking a significant step towards developing a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology [1][2]. Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its BNA™ technology for diagnostics and treatment monitoring [3][4]. - The company has built a comprehensive database of brain wave tests and secured patent protection over the past 15 years, now targeting pharmaceutical companies and medical practitioners for commercial use [3]. Acquisition Details - The acquisition of Evoke will enhance Firefly's assets, including a more than two-fold increase in proprietary brain scans, a three-fold increase in patents, and a ten-fold increase in commercial sites [2]. - The purchase terms include a total payment of $6 million, split 50% in cash and 50% in Firefly's common stock priced at $3.50 per share, along with a potential $500,000 earn-out for Evoke's investors based on future revenue performance [5]. Technological Synergies - The integration of Evoke's technologies is expected to create significant technological, clinical, and commercial synergies, enhancing Firefly's capabilities in brain health assessment [2]. - Firefly's BNA™ technology utilizes AI and machine learning on a proprietary database of over 17,000 patients, providing comprehensive insights into brain function and improving diagnostic accuracy for mental and cognitive disorders [4]. Market Position - Firefly possesses the largest known proprietary database of over 180,000 standardized EEG/ERP assessment records and has 27 granted patents, positioning the company strongly in the brain health technology market [5].